ACW 1.75% 5.6¢ actinogen medical limited

Boom in brain drugs

  1. 1,181 Posts.
    lightbulb Created with Sketch. 706
    Just posted on the NEU thread that they received Orphan Drug designation for their Rett Syndrome drug. They are leading the way in brain drug development on the ASX but ACW is poised to follow closely behind soon and coming off a miniscule market cap of 31 mill its a must buy in boom that is about to take place in brain drugs. Alzheimer's Dementia is a massive unmet market and ACW may just have the breakthrough into a multi billion $$ market whilst finding a treatment that can reduce the suffering and burden that this disease causes globally.

    With the Welcome trust having invested 25 mill over 7 years a market cap of 31 mill for ACW is way below odds and i see a upsurge coming on the back of NEU's success but also on the back of ACW's own developments with clinical trial results due mid year. Not forgetting we have had Dr Bill Ketelbey join the board who's past roles in Pfizer and its development of its Alzheimer's drug Aricept shows the potential that someone of his caliber sees in Xanamem.

    With a top 20 holding 70% of stock the upside in ACW is huge and on the back of NEU and the brain drug boom that is opening up i am happy to be in here at the ground floor. I expect a move to a 100 mill market cap by mid year as clinical results come through.
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Mkt cap $55.89M
Open High Low Value Volume
5.9¢ 5.9¢ 5.6¢ $10.18K 179.6K

Buyers (Bids)

No. Vol. Price($)
1 125000 5.5¢

Sellers (Offers)

Price($) Vol. No.
5.6¢ 10000 1
Last update - 15.26pm 18/01/2019 (20 minute delay) ?
-0.00 ( 3.45 %)
Open High   Low Volume
5.8¢ 5.8¢   5.6¢ 29622
Last updated 13.50pm 18/01/2019 (live) ?
ACW (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.